NCT00758199View on ClinicalTrials.gov

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Cataracts
Interventions
DRUG

Bromfenac

Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks

DRUG

Moxifloxacin hydrochloride

Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.

DRUG

Prednisolone Acetate

Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).

Trial Locations (1)

94024

Altos Eye Physicians, Los Altos

Sponsors

Lead Sponsor

Bp Consulting, Inc
All Listed Sponsors
lead

Bp Consulting, Inc

NETWORK

NCT00758199 - Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery | Biotech Hunter | Biotech Hunter